Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease - Wikidata - wikimedia - TriplyDB

Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease

Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease

http://www.wikidata.org/entity/Q28266116

about

Emerging therapies for fibromyalgia: an update.New non-oral drug delivery systems for Parkinson's disease treatment.Rotigotine transdermal patch: a review of its use in the treatment of Parkinson's disease.Effects of rotigotine on Parkinson's disease-related sleep disturbances.A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease.Clinical pharmacology and efficacy of rotigotine (Neupro® patch) in the treatment of restless leg syndrome.Highly Enantioselective Iridium-Catalyzed Hydrogenation of Cyclic Enamides.The efficacy and tolerability of rotigotine on patients with periodic limb movement in sleep: A systematic review and meta-analysis.

P2860

Q37756999-EDC55F43-A6B2-4E1C-8AEE-9964F07BEE12 Q37840165-67F642DF-89D5-48AA-8698-F77DA9F63CCF Q37905769-8ECD8EE3-57CA-44DD-83D2-ABE200DC51D8 Q38153751-9C035758-DE50-4618-AC2F-31ACA775033F Q38662579-E466C028-DE35-4E16-9104-93CA5696AC7F Q38844082-A01ACA88-A527-4C28-A765-1A7A866BF42E Q41607875-765747BD-F3C4-4125-A8AF-BE4FB1D6E887 Q55302709-0A66FC6F-0DC7-4D03-ABD9-1B36246CEF32

P2860

Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease

http://www.wikidata.org/entity/Q28266116

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Transdermal rotigotine: a clin ...... agement of Parkinson's disease

@ast

Transdermal rotigotine: a clin ...... agement of Parkinson's disease

@en

Transdermal rotigotine: a clin ...... agement of Parkinson's disease

@nl

type

label

Transdermal rotigotine: a clin ...... agement of Parkinson's disease

@ast

Transdermal rotigotine: a clin ...... agement of Parkinson's disease

@en

Transdermal rotigotine: a clin ...... agement of Parkinson's disease

@nl

prefLabel

Transdermal rotigotine: a clin ...... agement of Parkinson's disease

@ast

Transdermal rotigotine: a clin ...... agement of Parkinson's disease

@en

Transdermal rotigotine: a clin ...... agement of Parkinson's disease

@nl

P1433

Q28266116-D0DD20EA-BE72-43BF-BEF2-E4E95EFB4235

P1476

Q28266116-DDB5A2F8-BE7B-4EF9-B8E1-F7CBDDA3EF10

P2093

Q28266116-0543F2FF-EC73-460B-8A13-B7B3040BB6C8

Q28266116-1952BF5E-E20C-4492-BCB8-A87130C110AD

Q28266116-9066D239-5427-4DBB-978E-69A97C08A02C

Q28266116-F761F0D3-BC4F-466B-A504-6E400838ED30

P2860

Q28266116-02859481-F25A-4C7A-B1C0-FB63708DDD0A

Q28266116-08FDB0D5-73DF-4437-8951-CCC7A30DC498

Q28266116-14583BC5-58F4-4199-B755-71ACE7DB257B

Q28266116-1B94CD88-E46C-44D6-AE1F-2D701F30D2FA

Q28266116-236DF1FB-9C8B-4408-9409-73AEE46FA120

Q28266116-268355CA-5B3D-4C7F-88DE-1D70D65E6641

Q28266116-26D3FFDB-104D-4915-9BAB-E5F138FF51B1

Q28266116-28BABB0F-2941-4A44-994E-D369FF4A2CBE

Q28266116-3C7FF87E-0032-46BF-9F2A-288B452FF3A4

Q28266116-42CAB150-A514-4D5D-8ED1-98DA4188BAB9

P304

Q28266116-06B5FA40-23CE-4106-B249-CC7AA34B2F2D

P31

Q28266116-0BE8ACDA-97A1-4FDD-B9DB-3B7D1E0CCD8C

P356

Q28266116-73F59CAD-302D-4056-866E-E5774F836384

P407

Q28266116-95152128-2B51-4932-8C49-0BD15738CBF6

P433

Q28266116-4E27F8A4-7469-4DFB-832E-1028FF4ACD58

P478

Q28266116-AAD5C441-6925-421B-B800-6404555EA317

P577

Q28266116-97080734-AECF-49D1-AA61-8395CE4A3CF8

P698

Q28266116-4A836CCE-BC97-4DE3-B95C-A648A735FED5

P921

Q28266116-72B6B2CC-D41C-4A7B-9397-39CFAFC9126B

Q28266116-a988aaac-cad6-4309-93b6-cfe08a49a46b

P356

PHCO.29.12.1452

P1433

Pharmacotherapy

P1476

Transdermal rotigotine: a clin ...... agement of Parkinson's disease

@en

P2093

David M Swope

http://www.w3.org/2001/XMLSchema#string

Jack J Chen

http://www.w3.org/2001/XMLSchema#string

Kelly E Lyons

http://www.w3.org/2001/XMLSchema#string

Khashayar Dashtipour

http://www.w3.org/2001/XMLSchema#string

P2860

A controlled trial of rotigotine monotherapy in early Parkinson's disease

Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes

The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease

Behavioural assessment of mice lacking D1A dopamine receptors

Transdermal administration of bromocriptine.

One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome.

Translating safety, efficacy and compliance into economic value for controlled release dosage forms.

Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.

Clinical practice. Diagnosis and initial management of Parkinson's disease.

Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications.

P304

1452-67

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1592/PHCO.29.12.1452

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2009-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19947805

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease